Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 2/20 | 0.33 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497862 | 0.81 | APLNR (0.46) | PDE2AAPLNRLMNATP53HTT | |
| SCHEMBL737515 | 0.74 | HSD17B10 (0.42) | HSD17B10TTRLMNACYP1A2CYP3A4 | |
| SCHEMBL1100314 | 0.74 | CYP3A4 (0.36) | APLNRLMNATP53HTTCYP3A4 | |
| SCHEMBL2497084 | 0.74 | AAK1 (0.41) | — | |
| SCHEMBL1100412 | 0.72 | APLNR (0.36) | APLNR | |
| SCHEMBL69021 | 0.72 | ESR1 (0.63) | ESR1HSD17B10ESR2PDE2ATTR | |
| SCHEMBL6742674 | 0.72 | ESR1 (0.63) | ESR1HSD17B10ESR2PDE2ATTR | |
| SCHEMBL30234474 | 0.72 | ESR1 (0.63) | ESR1HSD17B10ESR2PDE2ATTR | |
| SCHEMBL3342503 | 0.70 | APLNR (0.35) | APLNR | |
| SCHEMBL2499335 | 0.68 | PDE2A (0.43) | PDE2ALMNATP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813613-B1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-8030327-B2 | 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle | MDS K.K. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1813613-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103136-A1 | Novel Fused Imidazole Derivative | HRH4, H1-4, H1-3 | ESR1 454/4885HSD17B10 1655/4885ESR2 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.